KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAsset Writedowns and ImpairmentAsset Writedowns and ImpairmentCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesChange in TaxesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionDivestmentsDividends Paid - CommonDividends Paid - CommonExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesLong-Term Debt IssuancesLong-Term Debt RepaymentsNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesShare-based CompensationShare-based CompensationShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueEBIATGross ProfitLeasesLong-Term Debt IssuancesLong-Term Debt RepaymentsMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)R&D In ProcessReceivables - NetReceivables - OtherShares OutstandingShares OutstandingShort-Term Debt issuances
Ratios

Bristol Myers Squibb (BMY) Short-Term Debt issuances (2016 - 2026)

Bristol Myers Squibb has reported Short-Term Debt issuances over the past 18 years, most recently at $321.0 million for Q1 2026.

  • Quarterly Short-Term Debt issuances fell 12.77% to $321.0 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was -$47.0 million through Mar 2026, up 98.13% year-over-year, with the annual reading at $99.0 million for FY2024, 182.5% up from the prior year.
  • Short-Term Debt issuances was $321.0 million for Q1 2026 at Bristol Myers Squibb, up from -$431.0 million in the prior quarter.
  • Over five years, Short-Term Debt issuances peaked at $3.0 billion in Q1 2024 and troughed at -$2.6 billion in Q2 2024.
  • The 5-year median for Short-Term Debt issuances is $42.0 million (2022), against an average of $17.6 million.
  • The largest YoY upside for Short-Term Debt issuances was 2233.59% in 2024 against a maximum downside of 2341.74% in 2024.
  • A 5-year view of Short-Term Debt issuances shows it stood at -$58.0 million in 2022, then plummeted by 508.62% to -$353.0 million in 2023, then fell by 14.73% to -$405.0 million in 2024, then dropped by 6.42% to -$431.0 million in 2025, then soared by 174.48% to $321.0 million in 2026.
  • Per Business Quant, the three most recent readings for BMY's Short-Term Debt issuances are $321.0 million (Q1 2026), -$431.0 million (Q4 2025), and $431.0 million (Q3 2025).